摘要
目的:探讨血清前梯度蛋白2(AGR2)、磷酸甘油酸激酶1(PGK-1)、髓样相关蛋白8/14(MRP8/14)表达情况与前列腺癌(PCa)患者术后疗效评估及生存情况的相关性。方法:选取2016年1月至2017年1月收治的83例PCa患者为PCa组,另选取64例良性前列腺增生(BPH)患者为BPH组,50例健康男性为对照组,测定所有研究对象血清AGR2、PGK1、MRP8/14水平,分析其与PCa患者术后疗效及生存情况相关性。结果:PCa组血清AGR2、PGK1、MRP8/14水平明显高于BPH组、对照组(P<0.05);PCa患者血清AGR2水平与前列腺特异性抗原(PSA)水平、分化程度、淋巴结转移、骨转移、TNM分期有关,血清PGK1水平与PSA水平、淋巴结转移、侵袭、骨转移、TNM分期有关,血清MRP8/14水平与PSA水平、淋巴结转移、骨转移、TNM分期有关(P<0.05);PCa组术后血清AGR2、PGK1、MRP8/14水平明显降低(P<0.05);随访9~35个月,平均(22.48±4.27)个月,Kaplan-Meier生存曲线显示,高血清AGR2、PGK1、MRP8/14水平组总生存率明显低于低血清AGR2、PGK1、MRP8/14水平组(P<0.05);多因素Cox回归分析显示,PSA(HR=0.356,95%CI=0.372~0.953)、骨转移(HR=1.642,95%CI=1.025~2.615)、AGR2(HR=3.441,5%CI=0.085~23.154)、PGK1(HR=4.386,5%CI=0.924~20.536)、MRP8/14(HR=2.758,95%CI=1.035~20.625)为PCa患者预后风险因素(P<0.05);ROC曲线显示,血清AGR2+PGK1+MRP8/14水平(AUC=0.911,95%CI=0.850~0.954)诊断PCa的敏感度、特异度、准确度高于AGR2(AUC=0.783,95%CI=0.704~0.850)、PGK1(AUC=0.794,95%CI=0.716~0.859)、MRP8/14(AUC=0.770,95%CI=0.689~0.838)单独诊断。结论:血清AGR-2、PGK1、MRP8/14水平变化与PCa患者术后疗效和生存情况密切相关,联合检测进而提升PCa诊断价值。
Objective: To investigate the relationship between the expression of anterior gradient 2(AGR2), phosphoglycerate kinase 1(PGK-1), myeloid-related protein 8/14(MRP8/14) and postoperative curative effect and survival assessment in patients with prostate cancer(PCa). Methods: A total of 83 PCa patients admitted to our hospital(January 2016 to January 2017) were selected as the PCa group, another 64 patients with benign prostatic hyperplasia(BPH) were selected as the BPH group, and 50 healthy men were selected as the control group. The serum AGR2, PGK1, and MRP8/14 levels of all subjects were analyzed and their correlation with postoperative efficacy and survival of PCa patients was analyzed. Results: The serum AGR2, PGK1, and MRP8/14 levels in the PCa group were significantly higher than those in the BPH group and the control group(P<0.05). The serum AGR2 level in PCa patients was related to PSA levels, degree of differentiation, lymph node metastasis, bone metastasis, and TNM staging. Serum PGK1 level was related to PSA level, lymph node metastasis, invasion, bone metastasis, and TNM staging. Serum MRP8/14 level was related to PSA level, lymph node metastasis, bone metastasis and TNM staging(P<0.05). Postoperative serum AGR2, PGK1 and MRP8/14 levels in the PCa group significantly decreased(P<0.05). All patients received follow-up for 9 to 35 months with an average of(22.48±4.27) months. Kaplan-Meier survival curve showed that the overall survival rate of the group with high serum AGR2, PGK1 and MRP8/14 levels was significantly lower than that with low serum AGR2, PGK1 and MRP8/14 levels Group(P<0.05). Multivariate Cox regression analysis showed that PSA(HR=0.356, 95%CI=0.372-0.953), bone metastasis(HR=1.642, 95%CI=1.025-2.615), AGR2(HR=3.441, 95%CI=0.085-23.154), PGK1(HR=4.386, 95%CI=0.924-20.536) and MRP8/14(HR=2.758, 95%CI=1.035-20.625) were prognostic risk factors for PCa patients(P<0.05). ROC curve showed that the serum AGR2+PGK1+MRP-8/14 level(AUC=0.911, 95%CI=0.850-0.954) was more sensitive, specific, and accurate in diagnosing PCa than AGR2(AUC=0.783, 95%CI=0.704-0.850), PGK1(AUC=0.794, 95%CI=0.716-0.859), MRP8/14(AUC=0.770, 95%CI=0.689-0.838) separately. Conclusion: The changes of serum AGR2, PGK1, and MRP8/14 levels might be closely related to the postoperative efficacy and survival of PCa patients. Combined detection could enhance the diagnostic value of PCa.
作者
顾安琪
梅迪
黄健
GU Anqi;MEI Di;HUANG Jian(Department of Laboratory Medicine,Jiangyin Hospital of Traditional Chinese Medicine,Jiangyin,214400,China)
出处
《临床血液学杂志》
CAS
2021年第2期121-126,共6页
Journal of Clinical Hematology
